Quantcast
Search Daily Dose & Film Annex
Loading

BIO SmartBrief

Daily Dose Newsletter

Monday
Dec192011

Fate Therapeutics - William Rastetter becomes Chairmen & Interim CEO

William Rastetter PhD is best known for his time at Idec Pharmaceuticals (can you say rituxan). He is considered a heavyweight in the biotechnology world so his willingness to take on this role at Fate Therapeutics is not only positive for Fate but for the industry overall. Fate Therapeutics is working on ProHema (umbilical cord blood transplants (UCB), with data recently presented at ASH.

PrintView Printer Friendly Version

EmailEmail Article to Friend

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Post:
 
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>
« Immunocellular ($IMUC) - Moving forward in Brain Cancer | Main | Stem Cells Inc. (STEM): Prices $10M secondary at $1.25 »